Overview of Dr. Abuhadra
Dr. Nour Abuhadra is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, Cleveland Clinic, University of Texas M.D. Anderson Cancer Center, and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from Weill Cornell Medical College in Qatar and has been in practice 1 year. She is one of 188 doctors at Cleveland Clinic and one of 407 doctors at University of Texas M.D. Anderson Cancer Center who specialize in Oncology. She has more than 20 publications and over 150 citings.
Office
Evelyn H. Lauder Breast Center at Memorial Sloan Kettering Cancer Center
300 East 66th Street
New York, NY 10021- Is this information wrong?
Education & Training
Cleveland Clinic FoundationResidency, Internal Medicine, 2015 - 2018
Weill Cornell Medical College in QatarClass of 2015
Certifications & Licensure
FL State Medical License 2021 - Present
NJ State Medical License 2021 - 2025
NY State Medical License 2021 - 2024
OH State Medical License 2015 - 2018- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Susan Papizan Dolan Fellowship in Breast Oncology (Recognition of Research Excellence) University of Texas - MD Anderson Cancer Center, 2020
- ASCO Employees Conquer Cancer Foundation Merit Award American Society of Clinical Oncology, 2020
- Research Merit Award European Society Of Medical Oncology, 2020
- Join now to see all
Publications & Presentations
PubMed
- 1 citationsPredictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospecti...Nour Abuhadra, Ryan Sun, Clinton Yam, Gaiane M Rauch, Qingqing Ding, Bora Lim, Alastair M Thompson, Elizabeth A Mittendorf, Beatriz E Adrada, Senthil Damodaran, Kiran ...> ;Cancers. 2023 Jun 21
- 3 citationsMolecularly Targeted Therapies for Triple Negative Breast Cancer: History, Advances, and Future Directions.Nicholas Mai, Nour Abuhadra, Komal Jhaveri> ;Clinical Breast Cancer. 2023 Dec 1
- Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy.Nour Abuhadra, Ryan Sun, Roland L Bassett Jr, Lei Huo, Jeffrey T Chang, Mediget Teshome, Alyson R Clayborn, Jason B White, Elizabeth E Ravenberg, Beatriz E Adrada, Ros...> ;Investigational New Drugs. 2023 Jun 1
- Join now to see all
Journal Articles
- Impact of social media for the hematologist/oncologist.Abuhadra, N et al, Seminars in Hematology, 10/1/2017
Abstracts/Posters
- Prognostic impact of high stromal tumor-infiltrating lymphocytes (sTIL) in the absence of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in early stag...Abuhadra, N et al, ASCO 2020, Chicago, IL. USA, 5/31/2020
- The Immunomodulatory (IM) Signature Enhances Prediction of Pathologic Complete Response (pCR) to Neoadjuvant Therapy (NAT) in Triple Negative Breast Cancers (TNBC) wit...Abuhadra, N et al, ESMO Breast Conference (Oral Presentation), Madrid, Spain (Virtual due to COVID-19), 5/1/2020
- Serial TILs: Evaluating the role of mid-treatment tumor infiltrating lymphocytes (TIL) in predicting pathologic complete response (pCR) in early-stage triple negative ...Abuhadra, N et al, San Antonio Breast Cancer Symposium, Texas, USA, 12/8/2019
- Join now to see all
Research History
- Developing patient selection strategies for chemotherapy de-escalation in early-stage triple-negative breast cancer.2018 - 2020
Hospital Affiliations
Memorial Sloan Kettering Cancer CenterNew York, New York
Cleveland ClinicCleveland, Ohio
University of Texas M.D. Anderson Cancer CenterHouston, Texas- Memorial Hospital for Cancer and allied DiseasesBasking Ridge, New Jersey
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
